Figure 4.
Cell viability of MCF7 breast cancer cells following treatment with either AMD3100 or the CXCR4 blocking mAb. Cells were treated with (A) CXCR4 antagonist AMD3100 (0.5 - 100 nM) and (B) the blocking mAb, MAB172 (2.5 - 20 μg/ml) for 24 hrs at 5% CO2 at 37°C. Control IgG2b mAb, MAB004 (10 μg/ml) was used as the control. Data are expressed as the mean ± SD of duplicate samples and are representative of three independent experiments. *p < 0.05 versus (A) culture medium (CM) or (B) control mAb (IgG) treated cells.